Skip to main content

Table 3 LncRNA expression level and clinical feature analysis of 22 cases of LADC from Xiangya hospital

From: Identification of LINC02310 as an enhancer in lung adenocarcinoma and investigation of its regulatory network via comprehensive analyses

Clinical features

lnc-YARS2-5

lnc-NPR3-2

LINC02310

Low

High

p1

p2

Low

High

p1

p2

Low

High

p1

p2

Age

            

  < 55

 

1

5

0.615

0.457

3

5

 > 0.99

0.636

2

6

 > 0.99

 > 0.99

  ≥ 55

 

4

8

3

8

3

9

Gender

            

 Male

 

4

8

0.615

0.457

6

7

0.109

0.044

5

9

0.260

0.091

 Female

 

1

5

0

6

0

6

T-stage

            

 T1

 

5

4

0.029

0.009

1

8

0.141

0.069

0

10

0.033

0.010

 T2/T3/T4

 

0

9

5

5

5

5

N-stage

            

 N0

 

5

7

0.114

0.063

1

10

0.041

0.013

2

11

0.290

0.176

 N1/N2/N3

 

0

6

5

3

3

4

TNM-stage

            

 I

 

4

4

0.118

0.060

1

7

0.177

0.127

0

9

0.038

0.020

 II/III/IV

 

1

9

5

6

5

6

Differentiation

            

 Low

 

1

5

0.542

0.395

2

4

 > 0.99

0.937

2

4

0.346

0.310

 Mid-low

 

1

2

1

2

1

2

 Mid

 

1

3

2

2

0

4

 Mid-high

 

1

0

1

1

2

1

  1. ‘Low’ and ‘high’ denote the cases where the DElncRNAs were low expressed and high expressed, respectively. p1 and p2 are the p-values obtained via Fisher’s accurate test and Pearson’s chi-squared test, respectively
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us